Mesoblast Limited (MESO) News
Mesoblast Limited (MESO)
Today's Latest Price: $15.28 USD
Updated Nov 25 4:00pm
Add MESO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter MESO News Items
MESO News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MESO News From Around the Web
Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.
Mesoblast plunges on FDA recommendation of additional study for remestemcel-L in SR-aGVHDThe FDA has issued a Complete Response Letter to Mesoblast's (MESO) Biologics License Application ((BLA)) for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).While the Oncologic Drugs Advisory Committee of the FDA voted 9:1 that the available data support the efficacy of remestemcel-L in pediatric... |
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine UpdatesBiotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. ... |
Mesoblast (ASX:MSB) wins Biotech award for Remestemcel-L15 Sep 2020 - Mesoblast (ASX:MSB), today announced that its lead product candidate remestemcel-L has been selected as the winner of the Fierce Innovation Awards - Life Sciences Edition 2020 for Biotech Innovation. |
Late-stage study of Mesoblast cell therapy in COVID-19 to continue as isThe independent Data Safety Monitoring Board has completed its first interim analysis of data from a Phase 3 clinical trial evaluating Mesoblast Limited's ([[MESO]] -0.3%) remestemcel-L, an allogeneic mesenchymal stem cell product derived from bone marrow, in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome ((ARDS)).Based on preliminary results from... |
Mesoblast's (ASX:MSB) good COVID-19 news | Rask MediaMesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients. |
Buy, hold, sell: Telstra, CSL, Mesoblast, Dacian Gold, EML PaymentsThese stocks are the most searched-for on Livewire Markets – but are they a buy? |
Mesoblast nabs ethics approval to treat COVID-19 patients in AustraliaMesoblast (MESO) has received approval from the Human Research Ethics Committee of Monash Health to include Australian hospitals in the Phase 3 trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome ((ARDS)). Up to 300 patients are expected to be enrolled in this late-stage study.The clinical protocol... |
The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPOScaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics... |
Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS). |
Mesoblast Before The PDUFAMesoblast's (MESO) stock has grown over 300% since we last made out an investment case in March 2019, and an IOM runthrough six months prior, based on phase 2 trial data in acute graft versus host disease (aGVHD). Presently, the United States Food and Drug Administration ((FDA)) has accepted the... |
